In an update Tuesday, Pfizer said it is discontinuing 15 of the projects in its development pipeline. The news comes a month after the world's largest pharmaceutical company announced large research and development cuts were on the way.
Pharmaceutical companies looking for fresh sources of profit are increasingly investing in a range of health care innovations that aren't drugs at all, from smartphone apps and educational websites to social media platforms and wireless devices, reports Ernst & Young.
Pharmaceutical giant Roche said Friday that it would delay an FDA filing for its new diabetes drug for 12 to 18 months due to safety concerns. The beneficiary of Roche's misfortune is rival Amylin, which now jumps ahead in the race to get first approval of a once-weekly injectable type 2 diabetes drug.